Literature DB >> 29078641

Robotic assisted lobectomy for locally advanced lung cancer.

Giulia Veronesi1, Pierluigi Novellis1, Orazio Difrancesco2, Mark Dylewski3.   

Abstract

Some series report the use of video-assisted thoracic surgery (VATS) in patients with locally advanced non-small cell lung cancer (NSCLC) but, few studies describe the use of the robotic approach specifically for locally advanced disease. One potential advantage of the robotic approach over traditional VATS is the increased radicality. While the benefit of the robotic approach over open thoracotomy is directly related to reduced surgical trauma and the improved tolerability in fragile patients that have received induction treatment. In case of occult N2 disease, robotic assisted surgery can translate into a quicker recovery with improved compliance with adjuvant treatments following surgery. Technical details are reported and described. The robotic instrument technology allows sharp and controlled dissection compared to the typical blunt sweeping methods used in most VATS lobectomy techniques. The authors believe that robotic technology favors a more radical resection in the case of complex locally advanced tumors. Robotic technology has some limitations that have affected adoption such as significant capital and maintenance costs, reduced operating room efficiencies, and a steep learning curve.

Entities:  

Keywords:  Lung cancer; locally advanced; multimodality treatment; robotic surgery

Year:  2017        PMID: 29078641      PMCID: PMC5638314          DOI: 10.21037/jovs.2017.04.03

Source DB:  PubMed          Journal:  J Vis Surg        ISSN: 2221-2965


  33 in total

Review 1.  European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer.

Authors:  Dirk De Ruysscher; Corinne Faivre-Finn; Ursula Nestle; Coen W Hurkmans; Cécile Le Péchoux; Allan Price; Suresh Senan
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Is lobectomy by video-assisted thoracic surgery an adequate cancer operation?

Authors:  R J McKenna; R K Wolf; M Brenner; R J Fischel; P Wurnig
Journal:  Ann Thorac Surg       Date:  1998-12       Impact factor: 4.330

3.  VATS lobectomy reduces cytokine responses compared with conventional surgery.

Authors:  A P Yim; S Wan; T W Lee; A A Arifi
Journal:  Ann Thorac Surg       Date:  2000-07       Impact factor: 4.330

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  Comparing robot-assisted thoracic surgical lobectomy with conventional video-assisted thoracic surgical lobectomy and wedge resection: results from a multihospital database (Premier).

Authors:  Scott J Swanson; Daniel L Miller; Robert Joseph McKenna; John Howington; M Blair Marshall; Andrew C Yoo; Matthew Moore; Candace L Gunnarsson; Bryan F Meyers
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-08       Impact factor: 5.209

6.  Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Lary A Robinson; John C Ruckdeschel; Henry Wagner; Craig W Stevens
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

7.  Minimally invasive (robotic assisted thoracic surgery and video-assisted thoracic surgery) lobectomy for the treatment of locally advanced non-small cell lung cancer.

Authors:  Bernard J Park; Hao-Xian Yang; Kaitlin M Woo; Camelia S Sima
Journal:  J Thorac Dis       Date:  2016-04       Impact factor: 2.895

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.

Authors:  Herbert Decaluwé; Paul De Leyn; Johan Vansteenkiste; Christophe Dooms; Dirk Van Raemdonck; Philippe Nafteux; Willy Coosemans; Toni Lerut
Journal:  Eur J Cardiothorac Surg       Date:  2009-06-06       Impact factor: 4.191

10.  Difference in the impairment of vital capacity and 6-minute walking after a lobectomy performed by thoracoscopic surgery, an anterior limited thoracotomy, an anteroaxillary thoracotomy, and a posterolateral thoracotomy.

Authors:  Hiroaki Nomori; Takashi Ohtsuka; Hirotoshi Horio; Tsuguo Naruke; Keiichi Suemasu
Journal:  Surg Today       Date:  2003       Impact factor: 2.549

View more
  4 in total

1.  From "open" to robotic assisted thoracic surgery: why RATS and not VATS?

Authors:  Sara Ricciardi; Federico Davini; Carmelina Cristina Zirafa; Franca Melfi
Journal:  J Vis Surg       Date:  2018-05-22

2.  Current status of robot-assisted thoracoscopic surgery for lung cancer.

Authors:  Masato Kanzaki
Journal:  Surg Today       Date:  2019-03-11       Impact factor: 2.549

3.  Comparison of robotic-assisted lobectomy with video-assisted thoracic surgery for stage IIB-IIIA non-small cell lung cancer.

Authors:  Chongwu Li; Yingjie Hu; Jia Huang; Jiantao Li; Long Jiang; Hao Lin; Peiji Lu; Qingquan Luo
Journal:  Transl Lung Cancer Res       Date:  2019-12

4.  Clinical and economic comparative effectiveness of robotic-assisted, video-assisted thoracoscopic, and open lobectomy.

Authors:  Dao M Nguyen; Inderpal S Sarkaria; Chao Song; Rishindra M Reddy; Nestor Villamizar; Luis J Herrera; Lu Shi; Emelline Liu; David Rice; Daniel S Oh
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.